Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVRNASDAQ:LUCDNASDAQ:MDAINASDAQ:OBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVRAnteris Technologies Global$4.80+31.9%$3.89$2.34▼$8.79$173.10MN/A206,521 shs367,914 shsLUCDLucid Diagnostics$1.52-4.4%$1.35$0.68▼$1.80$164.45M1.28532,857 shs2.06 million shsMDAISpectral AI$1.47+0.7%$1.29$0.82▼$3.25$37.22M0.59841,655 shs161,553 shsOBIOOrchestra BioMed$2.82+3.7%$3.04$2.37▼$8.87$108.04M0.67165,567 shs174,835 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVRAnteris Technologies Global+31.87%+25.65%-3.61%-36.93%+479,999,900.00%LUCDLucid Diagnostics-4.40%+16.92%+14.29%+6.67%+65.96%MDAISpectral AI+0.68%+8.09%+16.67%-17.88%-9.26%OBIOOrchestra BioMed+3.68%-4.41%+1.44%-41.37%-46.79%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVRAnteris Technologies GlobalN/AN/AN/AN/AN/AN/AN/AN/ALUCDLucid Diagnostics3.2763 of 5 stars3.65.00.00.03.21.70.6MDAISpectral AI3.246 of 5 stars3.74.00.00.03.43.30.0OBIOOrchestra BioMed2.5577 of 5 stars4.63.00.00.01.60.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVRAnteris Technologies Global 3.00Buy$16.50243.75% UpsideLUCDLucid Diagnostics 3.20Buy$3.50130.26% UpsideMDAISpectral AI 3.33Buy$4.75223.13% UpsideOBIOOrchestra BioMed 3.20Buy$14.20403.55% UpsideCurrent Analyst Ratings BreakdownLatest MDAI, LUCD, OBIO, and AVR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025LUCDLucid DiagnosticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$2.00 ➝ $2.005/14/2025LUCDLucid DiagnosticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.00 ➝ $3.005/13/2025OBIOOrchestra BioMedChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.005/5/2025OBIOOrchestra BioMedBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$16.00 ➝ $12.004/23/2025OBIOOrchestra BioMedHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/22/2025OBIOOrchestra BioMedChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.004/21/2025LUCDLucid DiagnosticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $7.504/11/2025LUCDLucid DiagnosticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.00 ➝ $3.004/4/2025OBIOOrchestra BioMedHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $12.004/3/2025OBIOOrchestra BioMedB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/2/2025MDAISpectral AIHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.50 ➝ $3.50(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVRAnteris Technologies Global$2.71M63.85N/AN/AN/A∞LUCDLucid Diagnostics$4.17M39.41N/AN/A($0.47) per share-3.23MDAISpectral AI$29.96M1.24N/AN/A($0.10) per share-14.70OBIOOrchestra BioMed$2.89M37.44N/AN/A$1.90 per share1.48Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVRAnteris Technologies GlobalN/AN/A0.00N/AN/AN/AN/AN/AN/ALUCDLucid Diagnostics-$52.67M-$1.34N/AN/AN/A-1,069.87%N/A-123.54%8/11/2025 (Estimated)MDAISpectral AI-$20.85M-$0.54N/AN/AN/A-40.78%N/A-77.87%N/AOBIOOrchestra BioMed-$49.12M-$1.78N/AN/AN/A-2,179.33%-107.04%-70.88%N/ALatest MDAI, LUCD, OBIO, and AVR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025AVRAnteris Technologies GlobalN/A-$0.61N/A-$0.61N/AN/A5/12/2025Q1 2025OBIOOrchestra BioMed-$0.46-$0.49-$0.03-$0.49$0.39 million$0.87 million3/31/2025Q4 2024OBIOOrchestra BioMed-$0.43-$0.43N/A-$0.43$0.79 million$0.25 million3/27/2025Q4 2024MDAISpectral AI-$0.13-$0.06+$0.07-$0.41$6.83 million$7.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVRAnteris Technologies GlobalN/AN/AN/AN/AN/ALUCDLucid DiagnosticsN/AN/AN/AN/AN/AMDAISpectral AIN/AN/AN/AN/AN/AOBIOOrchestra BioMedN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVRAnteris Technologies GlobalN/AN/AN/ALUCDLucid DiagnosticsN/A1.181.14MDAISpectral AIN/A0.730.69OBIOOrchestra BioMedN/A4.234.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVRAnteris Technologies GlobalN/ALUCDLucid Diagnostics74.01%MDAISpectral AI67.08%OBIOOrchestra BioMed53.55%Insider OwnershipCompanyInsider OwnershipAVRAnteris Technologies GlobalN/ALUCDLucid Diagnostics6.80%MDAISpectral AI56.73%OBIOOrchestra BioMed8.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVRAnteris Technologies Global13836.06 millionN/AN/ALUCDLucid Diagnostics70108.19 million54.12 millionNo DataMDAISpectral AI8325.32 million8.04 millionNot OptionableOBIOOrchestra BioMed438.31 million35.47 millionNot OptionableMDAI, LUCD, OBIO, and AVR HeadlinesRecent News About These CompaniesHead to Head Contrast: SeaStar Medical (NASDAQ:ICU) vs. Orchestra BioMed (NASDAQ:OBIO)May 24, 2025 | americanbankingnews.comWhat is Chardan Capital's Forecast for OBIO FY2026 Earnings?May 18, 2025 | americanbankingnews.comOrchestra BioMed (NASDAQ:OBIO) Announces Quarterly Earnings ResultsMay 14, 2025 | marketbeat.comOrchestra BioMed Holdings - Breakthrough Device Designation Gives Speculative OptimismMay 14, 2025 | seekingalpha.comOrchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Tops Revenue EstimatesMay 12, 2025 | zacks.comOrchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical MilestonesMay 12, 2025 | globenewswire.comOrchestra BioMed Expands Patent Portfolio for AVIM Therapy, Gains FDA Breakthrough DesignationMay 11, 2025 | msn.comOrchestra BioMed Expands Patent Portfolio with 10 New Patents for Hypertension Treatment, Totaling 120 Global PatentsMay 9, 2025 | nasdaq.comWhy Orchestra BioMed Holdings, Inc.’s (OBIO) Stock Is Up 19.92%May 9, 2025 | aaii.comOrchestra BioMed’s AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart FailureMay 8, 2025 | finance.yahoo.comBarclays Has Lowered Expectations for Orchestra BioMed (NASDAQ:OBIO) Stock PriceMay 7, 2025 | marketbeat.comOrchestra BioMed's AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart FailureMay 7, 2025 | globenewswire.comOrchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?May 5, 2025 | zacks.comBoxer Capital Management LLC Makes New $953,000 Investment in Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO)May 4, 2025 | marketbeat.comOrchestra BioMed Secures FDA Clearance for Virtue Trial to Advance Coronary ISR TreatmentMay 1, 2025 | msn.comOrchestra BioMed to Present at Jefferies Global Healthcare ConferenceMay 1, 2025 | msn.comWhy Orchestra BioMed Holdings, Inc.’s (OBIO) Stock Is Up 7.51%May 1, 2025 | aaii.comFDA approves head-to-head trial of Orchestra BioMed’s balloonApril 30, 2025 | investing.comOrchestra BioMed (NASDAQ:OBIO) Shares Down 6.1% - Time to Sell?April 30, 2025 | marketbeat.comOrchestra BioMed wins FDA IDE for sirolimus-angioballoonApril 29, 2025 | massdevice.comOrchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated BalloonApril 29, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMDAI, LUCD, OBIO, and AVR Company DescriptionsAnteris Technologies Global NASDAQ:AVR$4.80 +1.16 (+31.87%) As of 05/27/2025 04:00 PM EasternAnteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.Lucid Diagnostics NASDAQ:LUCD$1.52 -0.07 (-4.40%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$1.54 +0.02 (+1.64%) As of 05/27/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.Spectral AI NASDAQ:MDAI$1.47 +0.01 (+0.68%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$1.47 0.00 (0.00%) As of 05/27/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Spectral AI, Inc., an artificial intelligence (AI) company, focuses on developing predictive medical diagnostics in the United States. The company develops medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers. Its products include DeepView System, a predictive analytics platform integrated with the predictive AI-Burn, which combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential and offers clinicians an objective and immediate assessment of a wound's healing potential prior to treatment or other medical intervention; and DeepView SnapShot M, a handheld, portable, and wireless diagnostic tool, that provides a potential enhanced and expanded use for the government and emergency care, first responders, and potentially home health care professionals. The company is headquartered in Dallas, Texas.Orchestra BioMed NASDAQ:OBIO$2.82 +0.10 (+3.68%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$2.82 +0.01 (+0.18%) As of 05/27/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft's Outlook Brightens as Analysts Boost Bullish Ratings Palantir Scores First $1 Billion Contract; Is It Priced In? Tesla: Why Analysts Think It Could Jump Another 47% Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook 3 Dividend Stocks to Get You Through Tariff Volatility Apple Sinks After New 25% Tariff Announcement—What's The Bottom? MarketBeat Week in Review – 05/19 - 05/23 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.